Month: April 2023

Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Annual General Meeting to be held on May 8, 2023 at 15.00 CEST at Westmanska Palatset, conference room Bryggarkungen, Holländargatan 17, Stockholm. Right to participate in the Annual General Meeting and notice of participation A shareholder who wishes to participate in the Annual General Meeting must (i) be recorded as a shareholder in the share register maintained by Euroclear Sweden AB relating to the circumstances on April 27, 2023, and (ii) no later than May 2, 2023 give notice by post to Bryggargatan 10, 111 21 Stockholm, Sweden, or via e-mail to ibt@ibtherapeutics.com. When providing such notice, the shareholder shall state name, personal or corporate registration number, address, telephone number and the number...

The Minister of Finance and Economic Affairs has presented a regulatory proposal in the government’s consultation portal on the plans to submit to Althingi a bill allowing for the liquidation and settlement of the IL-Fund. The settlement plans are in line with the assessment of the fund’s insolvency, revealed in a report presented by the minister to Parliament last October on the status of the fund. Further information on www.fjr.is 

AB “Ignitis grupė” (hereinafter – Group) informs that in the process of expanding and strengthening the competences of the Group Risk Management and Sustainability Committee (hereinafter – the Committee), the Supervisory Board of the Group approved two new independent members. From 1 April, the Committee was joined by Ana Riva and Wolf Willems, professionals with international experience in the fields of risk and environmental management, security and occupational health and safety. They were selected after performing the best in the selection announced at the turn of the year. The new members of the Committee will join the other two members currently working in the Committee, who were delegated by the Supervisory Board of Ignitis Group. “I believe that the new members will bring their competence and expertise to help Ignitis Group continue...

AB “Ignitis grupė” (hereinafter – Group) informs that in the process of expanding and strengthening the competences of the Group Risk Management and Sustainability Committee (hereinafter – the Committee), the Supervisory Board of the Group approved two new independent members. From 1 April, the Committee was joined by Ana Riva and Wolf Willems, professionals with international experience in the fields of risk and environmental management, security and occupational health and safety. They were selected after performing the best in the selection announced at the turn of the year. The new members of the Committee will join the other two members currently working in the Committee, who were delegated by the Supervisory Board of Ignitis Group. “I believe that the new members will bring their competence and expertise to help Ignitis Group continue...

Company announcement – No. 13 / 2023 Zealand Pharma A/S publishes a listing prospectus regarding admission to trading and official listing of 6,578,948 new shares on Nasdaq Copenhagen NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT; ANY PUBLIC OFFERING OF SUCH SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM THE ISSUER, WHICH WOULD CONTAIN DETAILED...